Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Novo Nordisk (NVO) Announces Results in Diabetes Studies

by Zacks Equity Research

Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

    Zacks Equity Research

    Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

    by Zacks Equity Research

    Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

      Zacks Equity Research

      Anika Reports Top Line Data from CINGAL Study, Shares Slump

      by Zacks Equity Research

      Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

        Tirthankar Chakraborty headshot

        4 of the Best Efficient Stocks to Buy for Superb Returns

        by Tirthankar Chakraborty

        We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

          Zacks Equity Research

          Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

          by Zacks Equity Research

          Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

            Zacks Equity Research

            Alexion (ALXN) Submits Application for ALXN1210 with FDA

            by Zacks Equity Research

            Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

              Zacks Equity Research

              Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

              by Zacks Equity Research

              Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

                Zacks Equity Research

                BSX or BAX: Which is a Better Pick for Your Portfolio Now?

                by Zacks Equity Research

                After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

                  Zacks Equity Research

                  Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

                  by Zacks Equity Research

                  Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

                    Zacks Equity Research

                    QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

                    by Zacks Equity Research

                    QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.